Catalog No.
DHB88001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
PFD, Adipsin, C3 convertase activator, Complement factor D, CFD, DF, Properdin factor D
Concentration
1.32 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00746
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AFD, Anti-fD, Anti-FACTOR D, FCFD4514S, RG7417, CAS: 1278466-20-8
Clone ID
Lampalizumab
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials, PMID: 29801123
Potential role of lampalizumab for treatment of geographic atrophy [Retraction], PMID: 26170604
Potential role of lampalizumab for treatment of geographic atrophy, PMID: 26089637
Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy, PMID: 26501510
Complement inhibition as a therapeutic strategy in retinal disorders, PMID: 30686077
Pharmacological Advances in the Treatment of Age-related Macular Degeneration, PMID: 31362645
Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy, PMID: 26535160
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy, PMID: 26359312
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials, PMID: 32199866
Antibodies to watch in 2017, PMID: 27960628
Antibodies to watch in 2018, PMID: 29300693
In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches, PMID: 30444371
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
[AMD and complement pathway in 2017], PMID: 29337453
Latest Developments in the Management of AMD, PMID: 29204992
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration, PMID: 28637922
Recent advances in the management and understanding of macular degeneration, PMID: 28491291
The role of the complement system in age-related macular degeneration, PMID: 24622760
Antibody therapies and their challenges in the treatment of age-related macular degeneration, PMID: 25725263
Corticosteroids and Anti-Complement Therapy in Retinal Diseases, PMID: 27815789
Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials, PMID: 29794727
Age-related macular degeneration foils drugmakers, PMID: 29121027
Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, PMID: 30383205
Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy, PMID: 27893095
Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics, PMID: 29148965
Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration, PMID: 25232192
Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study, PMID: 29530781
Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration, PMID: 25315664
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials, PMID: 32081489
Alterations in Extracellular Matrix/Bruch's Membrane Can Cause the Activation of the Alternative Complement Pathway via Tick-Over, PMID: 29721924
For research use only. Not for human or drug use.
